Modality
Radioligand
MOA
AuroraAi
Target
SGLT2
Pathway
Autophagy
GA
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
May 2020
→ May 2030
Phase 1Current
NCT08404777
900 pts·GA
2025-07→2030-05·Recruiting
NCT04413741
2,997 pts·GA
2020-05→2025-02·Terminated
3,897 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-051.1y agoInterim· GA
2030-05-244.1y awayInterim· GA
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Termina…
P1
Recruit…
Catalysts
Interim
2025-02-05 · 1.1y ago
GA
Interim
2030-05-24 · 4.1y away
GA
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08404777 | Phase 1 | GA | Recruiting | 900 | OS |
| NCT04413741 | Phase 1 | GA | Terminated | 2997 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |